CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in CNS Pharmaceuticals, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −9 vs. Q1 2024
- Shares held
- 144.2K
- −828.5K (−85.2%) vs. Q1 2024
- Total value
- $227.8K
- −$123.3K (−35.1%) vs. Q1 2024
- New holders
- 3
- 0 more added
- Sold out
- 12
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Anson Funds Management LP | 141,398 | $223.4K | 0.03% | +141,398 | New |
| UBS Group AG | 2,629 | $4.15K | 0.00% | +2,629 | New |
| Tower Research Capital LLC (TRC) | 115 | $182 | 0.00% | −6,657−98.3% | Reduced |
| Wells Fargo & Company | 4 | $6 | 0.00% | −237−98.3% | Reduced |
| Morgan Stanley | 2 | $3 | 0.00% | −65−97.0% | Reduced |
| Global Retirement Partners, LLC | 2 | $3 | 0.00% | −51−96.2% | Reduced |
| Bank of America Corp | 1 | $2 | 0.00% | −778−99.9% | Reduced |
| FMR LLC | 1 | $2 | 0.00% | −13−92.9% | Reduced |
| Plante Moran Financial Advisors, LLC | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 1 | $2 | 0.00% | +1 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −471,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −94,246−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −91,034−100.0% | Sold out |
| Smith Anglin Financial, LLC | 0 | $0 | 0.00% | −90,332−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −58,369−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −28,254−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −27,388−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −22,556−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −21,806−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −21,898−100.0% | Sold out |
| FSM Wealth Advisors, LLC | 0 | $0 | 0.00% | −19,084−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −18,729−100.0% | Sold out |